These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

692 related items for PubMed ID: 28576749

  • 1. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X, Wang X, Fang L, Lan C, Zheng X, Wang Y, Zhang Y, Han X, Liu S, Cheng K, Zhao Y, Shi J, Guo J, Hao J, Ren H, Nie G.
    Cancer Lett; 2017 Aug 28; 402():61-70. PubMed ID: 28576749
    [Abstract] [Full Text] [Related]

  • 2. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.
    Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
    Rozengurt E, Eibl G.
    World J Gastroenterol; 2019 Apr 21; 25(15):1797-1816. PubMed ID: 31057295
    [Abstract] [Full Text] [Related]

  • 8. Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer.
    Wang MT, Fer N, Galeas J, Collisson EA, Kim SE, Sharib J, McCormick F.
    Nat Commun; 2019 Jul 11; 10(1):3055. PubMed ID: 31296870
    [Abstract] [Full Text] [Related]

  • 9. Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation.
    Miyauchi S, Shien K, Takeda T, Araki K, Nakata K, Miura A, Takahashi Y, Kurihara E, Ogoshi Y, Namba K, Suzawa K, Yamamoto H, Okazaki M, Soh J, Tomida S, Yamane M, Sakaguchi M, Toyooka S.
    Anticancer Res; 2020 May 11; 40(5):2667-2673. PubMed ID: 32366411
    [Abstract] [Full Text] [Related]

  • 10. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, Chen X, Walsh AJ, Skala MC, Moses HL, Merchant NB.
    Gastroenterology; 2015 Dec 11; 149(7):1932-1943.e9. PubMed ID: 26255562
    [Abstract] [Full Text] [Related]

  • 11. Paraoxonase 2 Facilitates Pancreatic Cancer Growth and Metastasis by Stimulating GLUT1-Mediated Glucose Transport.
    Nagarajan A, Dogra SK, Sun L, Gandotra N, Ho T, Cai G, Cline G, Kumar P, Cowles RA, Wajapeyee N.
    Mol Cell; 2017 Aug 17; 67(4):685-701.e6. PubMed ID: 28803777
    [Abstract] [Full Text] [Related]

  • 12. Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer.
    Weiler SME, Pinna F, Wolf T, Lutz T, Geldiyev A, Sticht C, Knaub M, Thomann S, Bissinger M, Wan S, Rössler S, Becker D, Gretz N, Lang H, Bergmann F, Ustiyan V, Kalin TV, Singer S, Lee JS, Marquardt JU, Schirmacher P, Kalinichenko VV, Breuhahn K.
    Gastroenterology; 2017 Jun 17; 152(8):2037-2051.e22. PubMed ID: 28249813
    [Abstract] [Full Text] [Related]

  • 13. Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.
    Blasco MT, Navas C, Martín-Serrano G, Graña-Castro O, Lechuga CG, Martín-Díaz L, Djurec M, Li J, Morales-Cacho L, Esteban-Burgos L, Perales-Patón J, Bousquet-Mur E, Castellano E, Jacob HKC, Cabras L, Musteanu M, Drosten M, Ortega S, Mulero F, Sainz B, Dusetti N, Iovanna J, Sánchez-Bueno F, Hidalgo M, Khiabanian H, Rabadán R, Al-Shahrour F, Guerra C, Barbacid M.
    Cancer Cell; 2019 Apr 15; 35(4):573-587.e6. PubMed ID: 30975481
    [Abstract] [Full Text] [Related]

  • 14. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
    Rao G, Kim IK, Conforti F, Liu J, Zhang YW, Giaccone G.
    Eur J Cancer; 2018 Aug 15; 99():37-48. PubMed ID: 29902613
    [Abstract] [Full Text] [Related]

  • 15. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M, Cassant-Sourdy S, Duluc C, Fanjul M, Lulka H, Samain R, Roche C, Breibach F, Delisle MB, Poupot M, Dufresne M, Shimaoka T, Yonehara S, Mathonnet M, Pyronnet S, Bousquet C.
    Gastroenterology; 2015 Jun 15; 148(7):1452-65. PubMed ID: 25683115
    [Abstract] [Full Text] [Related]

  • 16. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G, Rodriguez-Canales J, Villalobos P, Neggers JE, Mendiratta S, Wei S, Landesman Y, Senapedis W, Baloglu E, Chow CB, Frink RE, Gao B, Roth M, Minna JD, Daelemans D, Wistuba II, Posner BA, Scaglioni PP, White MA.
    Nature; 2016 Oct 06; 538(7623):114-117. PubMed ID: 27680702
    [Abstract] [Full Text] [Related]

  • 17. Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC.
    Alhothali M, Mathew M, Iyer G, Lawrence HR, Yang S, Chellappan S, Padmanabhan J.
    Int J Mol Sci; 2019 May 16; 20(10):. PubMed ID: 31100813
    [Abstract] [Full Text] [Related]

  • 18. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
    Ischenko I, Petrenko O, Hayman MJ.
    Oncotarget; 2015 Jun 30; 6(18):15814-27. PubMed ID: 26158412
    [Abstract] [Full Text] [Related]

  • 19. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.
    Murakami S, Shahbazian D, Surana R, Zhang W, Chen H, Graham GT, White SM, Weiner LM, Yi C.
    Oncogene; 2017 Mar 02; 36(9):1232-1244. PubMed ID: 27546622
    [Abstract] [Full Text] [Related]

  • 20. Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer.
    Zhang X, Mao T, Xu H, Li S, Yue M, Ma J, Yao J, Wang Y, Zhang X, Ge W, Wang Y, Shentu D, Wang L.
    Aging (Albany NY); 2022 Apr 25; 14(8):3597-3606. PubMed ID: 35468095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.